Macroscopic to Microscopic – A Case of Crohn’s Disease Progressing to Collagenous Colitis

Murtaza Shabbir Hussain ¹, Harika Balagoni ², Sankalp Dwivedi ², Marc Piper ²

¹. Internal Medicine, Hurley Medical Center, Flint, USA  ². Gastroenterology, Ascension Providence Hospital, Southfield, USA

Corresponding author: Murtaza Shabbir Hussain, mhussai2@hurleymc.com

Abstract
The association between microscopic colitis (MC) and inflammatory bowel disease (IBD) is uncertain and infrequently reported. Rare cases in the literature consist of simultaneous MC and IBD, or progression of one condition to the other. We present a unique case of clinically and endoscopically diagnosed and successfully treated IBD that revealed MC on histology months later due to reappearance of diarrhea. Common pathophysiologic mechanisms, such as tumor necrosis factor α and T helper type 1 cells, may explain the MC and IBD relationship. During endoscopy, a prompt biopsy should be taken if suspicious for MC, thus decreasing the duration of patient’s symptoms and saving healthcare costs.

Categories: Gastroenterology
Keywords: microscopic colitis, inflammatory bowel disease, collagenous colitis, lymphocytic colitis, gi endoscopy

Introduction
In resource-poor countries, symptoms of diarrhea are one of the top leading causes of death due to severe dehydration, regardless of the cause. On the other hand, in resource-rich countries, diarrhea is more of an ‘inconvenience’ presenting as a common concern in ambulatory care. Majority of cases are infectious and of viral etiology. Noninfectious causes include malabsorption disorders, functional disorders, and organic disorders such as inflammatory bowel disease (IBD) and microscopic colitis (MC). MC is divided into collagenous colitis (CC) and lymphocytic colitis (LC) and presents as chronic, watery diarrhea but normal-appearing mucosa on colonoscopy [1,2]. IBD, classified into ulcerative colitis (UC) and Crohn’s disease (CD), is an autoimmune condition that clinically presents with abdominal pain, bloody or non-bloody diarrhea, weight loss, and evidence of inflammation on endoscopy. IBD and MC are distinct regarding their epidemiology, clinical manifestations, management, and pathology. There is a rare incidence of MC in known IBD patients and vice versa [3]. Equally as rare is the concurrent manifestation of IBD and MC.

We report a patient who was treated for clinically diagnosed CD. The recurrence of diarrheal symptoms resulted in further testing, which led to the diagnosis of CC.

Case Presentation
A 56-year-old-female with a history of anxiety and chronic smoking presented to our hospital with 12-day progressive, non-bloody diarrhea, 20-30 episodes/day including nocturnal episodes, associated with diffuse, cramping, lower abdominal pain. She denied fever, chills, sick contacts, travel, food contamination, medication changes, or recent antibiotics. She tried Imodium at home with no improvement. On presentation, she had mild leukocytosis, mild transaminitis, elevated C-reactive protein of 102 mg/L and fecal calprotectin 484 mcg/g. Computed tomography (CT) abdomen/pelvis did not show any acute abnormalities. Stool studies were negative for infection. She underwent esophagogastroduodenoscopy, which showed mild gastritis and duodenitis, biopsies negative for Helicobacter pylori and celiac disease.

Colonoscopy showed mild to moderate colitis with mucosal congestion, granularity, and cobble-stoning in a continuous and circumferential pattern from the rectum to the descending colon. Mild altered vascularity, congestion (edema), and friability were found as patches surrounded by normal mucosa in the transverse colon, ascending colon, and cecum with associated terminal ileitis (Figure 1). The ileocecal valve was stenotic and difficult to intubate. The limited visualized portion appeared normal. Biopsy revealed mild chronic active colitis negative for granulomas and dysplasia (Figure 2).
FIGURE 1: Initial colonoscopy demonstrating terminal ileitis
FIGURE 2: Hematoxylin and eosin stain biopsy reveals mild-chronic active colitis without granulomas or dysplasia

CT enterography showed narrowing of the terminal ileum with focal wall thickening and two more strictures in the small bowel. The patient was diagnosed with CD, started on IV steroids, and improved significantly. She was eventually transitioned to adalimumab outpatient. Three months later, she was readmitted with 10-day non-bloody diarrhea despite being compliant with adalimumab. After ruling out infections, including *Clostridium difficile*, she was started on oral steroids. Colonoscopy showed improved colitis from previous examination (Figure 3) but biopsy revealed increased subepithelial collagen plate with minimal mucosal distortion suggestive of CC (Figure 4).
She was started on budesonide in addition to adalimumab with no improvement. Review of medications.
showed selective serotonin reuptake inhibitor usage, which was discontinued. She was counseled to quit smoking but unsuccessful. Off the oral steroids, she continued to have 10–15 bowel movements. Trials of cholestyramine, bismuth, and loperamide were unsuccessful. Repeat colonoscopy showed endoscopically benign mucosa but continued presence of CC on biopsy. Given the refractoriness of symptoms, the patient was referred to a tertiary IBD center.

Discussion

MC is a clinicopathologic disorder, histologically subdivided into LC with increased intraepithelial lymphocytes (>20/100 colonic surface epithelial cells) and CC with atypically thickened subepithelial collagen band >10 μm [4]. MC is postulated to develop via an immunological response to various mucosal insults in predisposed patients [3]. LC, in particular, is associated with other autoimmune conditions such as celiac disease, psoriasis, and rheumatoid arthritis [3].

IBD manifests as endoscopically visible ulcerated mucosa, loss of vascularity, edema, friability, strictures, and so on. UC usually presents as bloody diarrhea while CD presents as fistulas, obstruction, and abdominal masses. Our patient initially presented with diarrhea, elevated inflammatory markers, and endoscopic and imaging findings consistent with CD. She was appropriately treated with IV steroids and adalimumab. Recurrence of her diarrhea prompted repeat colonoscopy, which revealed features of CC.

The relationship between IBD and MC is uncertain. MC could be a continuum of IBD; new-onset MC diagnosis was found after a median (range) of 20 (2–52) years in established IBD patients [1,5]. Conversely, established MC patients may also develop IBD, at a 17-fold increase in relative risk [6]. Additionally, cases of IBD patients in remission showed CC on biopsies [7]. Some MC patients reported a family history of UC [8], alluding to the role of genetic factors between the two.

Pathophysiologically, in MC, it is theorized that tumor necrosis factor-α (TNF-α) triggers the downregulation of tight junction proteins, claudin-4, -5, -8, increasing permeability, thus leading to diarrhea [9]. Permeability is also increased by non-steroidal anti-inflammatory drugs and proton-pump inhibitors, common MC triggers, that allow antigens to pass into the lamina propria provoking lymphocytosis [2]. Increased expression of TNF-α, interferon-γ, and the Th1-specific transcription factor T-BET in patients with MC who eventually developed IBD suggests a common immunological pathophysiological pathway in the MC-to-IBD transformation [3,10]. Few studies found associations between human leukocyte antigen haplotypes, DQ2 and DQ8, and risk of CC, LC, and IBD development [11-15]. Gut dysbiosis has been noted in both IBD and MC, again suggesting a common pathophysiological pathway [16-18]. The association between smoking and IBD is well established. Recent meta-analysis demonstrates that active smoking significantly increased incidence of MC with OR 3.58 [19].

Early consideration and diagnosis of MC in patients with IBD is important in tailoring the treatment regimen. Primary recommendation is cessation of potential triggers. For milder disease, cholestyramine, atropine/diphenoxylate, bismuth subsalicylate, and loperamide may be utilized. For moderate-to-severe disease, budesonide is recommended. Refractory patients require additional medications, such as infliximab, azathioprine, and methotrexate. Likewise, anti-TNF-α agents have demonstrated a good response rate [20]. The most severe cases, like poorly controlled IBD cases, require surgical diversion, colectomy, and diverting ostomy.

IBD has known complications such as malignancy and immune-mediated diseases such as ankylosing spondylitis and autoimmune thyroid disease. A systematic review showed an association between rheumatic diseases and MC [4,5], but no real conclusions can be made regarding MC and its association with classic IBD complications [4]. The complication rates and prognosis with MC-IBD overlap are unknown.

Conclusions

Our case highlights the possibility of development or co-existence of CC in a patient with CD. Whether MC is a spectrum of IBD or it is exacerbated by trigger factors is unclear. MC should be considered as a differential in IBD patients who were previously controlled or not responding to appropriate therapy presenting with chronic watery diarrhea. Prompt diagnosis can help early management of the disease and thereby improve quality of life for the patients and reduce healthcare costs.

Additional Information

Disclosures

Human subjects: Consent was obtained or waived by all participants in this study. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other
relationships or activities that could appear to have influenced the submitted work.

References

1. Wickbom A, Bohr J, Nyblin N, et al.: Microscopic colitis in patients with ulcerative colitis or Crohn's disease: a retrospective observational study and review of the literature. Scand J Gastroenterol. 2018, 53:410-6. 10.1080/00365521.2018.1430252

2. Megna B, Saha S, Wald A, Agni R, Matkowskyj KA, Caldera F: Symptomatic microscopic colitis atop quiescent inflammatory bowel disease: a case series. ACG Case Rep J. 2017, 4:e124. 10.14390/crj.2017.124

3. Li J, Yan Y, Meng Z, et al.: Microscopic colitis evolved into inflammatory bowel diseases is characterized by increased Th1/Tc1 cells in colonic mucosal lamina propria. Dig Dis Sci. 2017, 62:2755-67. 10.1007/s10620-017-4636-5

4. Solberg F, Ohlsson B: Microscopic colitis and its associations with complications observed in classic inflammatory bowel disease: a systematic review. Scand J Gastroenterol. 2020, 55:312-20. 10.1080/00365521.2020.1739325

5. Jegadeesan R, Liu X, Pagadala MR, Gutierrez N, Butt M, Navaneethan U: Microscopic colitis: is it a spectrum of inflammatory bowel disease? World J Gastroenterol. 2013, 19:4252-6. 10.3748/wjg.v19.i26.4252

6. Khalili H, Burke KE, Roelstraete B, Sachs MC, Olen O, Ludvigsson JF: Microscopic colitis and risk of inflammatory bowel disease in a nationwide cohort study. Gastroenterology. 2020, 158:1574-1583.e2. 10.1053/j.gastro.2019.12.028

7. Saad RE, Shobar RM, Jakate S, Mutlu EA: Development of collagenous colitis in inflammatory bowel disease: two case reports and a review of the literature. Gastroenterol Hepatol (Oxf). 2019, 7:218-22. 10.1095/gastro.go019.12.028

8. Olesen M, Eriksson S, Bohr J, Järnerot G, Tysk C: Lymphocytic colitis: a retrospective clinical study of 199 Swedish patients. Gut. 2004, 55:556-41. 10.1136/gut.2003.023440

9. Boland K, Nguyen GC: Microscopic colitis: a review of collagenous and lymphocytic colitis. Gastroenterol Hepatol (N Y). 2017, 13:671-7.

10. Carrasco A, Fernández-Baizares F: Th1 pathway: the missing link between inflammatory bowel disease and microscopic colitis?. Dig Dis Sci. 2017, 62:2609-11. 10.1007/s10620-017-4692-x

11. Fernández-Baizares F, Esteve M, Farré C, et al.: Predisposing HLA-DQ2 and HLA-DQ8 haplotypes of coeliac disease and associated enteropathy in microscopic colitis. Eur J Gastroenterol Hepatol. 2005, 17:1333-8. 10.1097/00042737-200512000-00011

12. Koskela RM, Karttunen TJ, Niemelä SE, Lehtola JK, Ilonen J, Karttunen RA: Human leucocyte antigen and TNFalpha polymorphism association in microscopic colitis. Eur J Gastroenterol Hepatol. 2008, 20:276-82. 10.1097/MEG.0b013e3282f2468d

13. Achkar JP, Kéli L, de Bakker PI, et al.: Amino acid position 11 of HLA-DRB1 is a major determinant of chromosome 6p association with ulcerative colitis. Genes Immun. 2012, 13:245-52. 10.1038/gene.2011.79

14. Goyette P, Boucher G, Mallon D, et al.: High-density mapping of the MHC identifies a shared role for HLA-DRB1*01:03 in inflammatory bowel diseases and heterozygous advantage in ulcerative colitis. Nat Genet. 2015, 47:172-9. 10.1038/ng.3176

15. Jostins L, Ripke S, Weersma RK, et al.: Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature. 2012, 491:119-24. 10.1038/nature11582

16. Morgan DM, Cao Y, Miller K, et al.: Microscopic colitis is characterized by intestinal dysbiosis. Clin Gastroenterol Hepatol. 2020, 18:984-6. 10.1016/j.cgh.2019.06.035

17. Millien V, Rosen D, Hsu J, Shah R: Proinflammatory sulfur-reducing bacteria are more abundant in colonic biopsies of patients with microscopic colitis compared to healthy controls. Dig Dis Sci. 2019, 64:432-8. 10.1007/s10620-018-5313-z

18. Rindom Krogsgaard L, Kristian Munck L, Bytzer P, Wildt S: An altered composition of the microbiome in microscopic colitis is driven towards the composition in healthy controls by treatment with budesonide. Scand J Gastroenterol. 2019, 54:446-52. 10.1007/s00357-2019-15990-4

19. Al Momani L, Balagoni H, Alomari M, et al.: The association between smoking and both types of microscopic colitis: a systematic review and meta-analysis. Arab J Gastroenterol. 2020, 21:9-18. 10.1016/j.ajg.2020.01.004

20. Esteve M, Mahadevan U, Sainz E, Rodriguez E, Salas A, Fernández-Baizares F: Efficacy of anti-TNF therapies in refractory severe microscopic colitis. J Crohns Colitis. 2011, 5:612-8. 10.1016/j.crohns.2011.05.001